On May 12, 2026, a paper published in The Lancet and presented at the European Congress of Endocrinology renamed polycystic ovary syndrome. After more than a decade of work and input from over 22,000 patients and clinicians worldwide, PCOS is now PMOS: polyendocrine metabolic ovarian syndrome.
One letter. It sounds like a technicality.
But the value of this change is not the acronym. It is the correction of an ovary-centered mental model for a condition that was never confined to the ovaries.
Why the Old Name Was a Problem
For decades, "polycystic ovary syndrome" told a misleading story. It pointed at the ovaries and implied cysts. What shows on ultrasound is not a cyst in the clinical sense. It is a collection of small antral follicles that stalled before ovulating.
That misnaming had consequences. Women were told their ovaries looked fine and sent home. Providers ordered a pelvic ultrasound, saw nothing dramatic, and closed the file. The WHO estimates that up to 70% of affected women worldwide remain undiagnosed. Seventy percent.
And the symptoms that actually shape daily life were never about cysts:
"If you spent years being dismissed because your ovaries looked fine on imaging, you were not wrong. Your symptoms were real. The name was the problem."
What Changed and What Didn't
This is the part worth being precise about, because the headlines have been loose with it.
The diagnostic criteria did not change. Diagnosis still rests on two of three findings: ovulatory dysfunction, clinical or biochemical androgen excess, and ovarian morphology, after other causes are excluded. Ultrasound was already optional in adults before this announcement, and it still is.
The treatment recommendations did not change. The international evidence-based guideline was updated in May 2026 to carry the new term. Its recommendations and content are unchanged. The 2028 guideline update will fold PMOS in as standard terminology.
Your diagnosis did not change. If you were diagnosed with PCOS, you have PMOS. Same condition, same criteria, same you. Nothing about the name change requires new testing or a new workup.
What changed is the frame. And frames drive behavior. A name that says "polyendocrine" and "metabolic" out loud makes it harder for a clinician to stop at a pelvic ultrasound and call it a day.
The Transition Timeline
This is a three-year rollout, not an overnight switch. Both terms will be in circulation for a while, which is why you will see PMOS and PCOS used together in most patient materials, including ours.
What a Real Evaluation Looks Like
If the new name means anything clinically, it means the workup should match the biology. An ultrasound alone was never an evaluation. Here is what a thorough one covers.
- Cycle and symptom history. Cycle length and regularity, onset and progression, acne and hair pattern changes, weight trajectory, and family history.
- Androgen assessment. Total and free testosterone, DHEA-S, SHBG, and 17-hydroxyprogesterone. Free testosterone matters here because SHBG is often low, which makes a "normal" total look reassuring when it is not.
- Exclusion testing. TSH and thyroid antibodies, prolactin, and where indicated cortisol assessment. Thyroid disease mimics enough of this picture that skipping it is how people get the wrong answer for years.
- Metabolic assessment. Fasting glucose and insulin, A1c, and a full lipid panel. Insulin resistance is common in lean women with PMOS, so body size is not a screening tool. Self-order lab panels are available if you want the data before a visit.
- Where this fits long term. Cardiometabolic risk in PMOS is a decades-long story, not a one-visit finding. Our biological age calculator is a starting point for seeing where you sit now.
The findings then drive the plan, whether that is hormone optimization, insulin-directed treatment through our medical weight loss program, targeted work on hair thinning and androgenic hair loss, or a combination. Treatment follows the phenotype in front of us, not the label.
PMOS After 40
This is the version I see most often in Dallas, and it gets missed constantly.
A woman reaches her early 40s having never been diagnosed. Her cycles were always a little unpredictable, so nobody flagged it. Now they are changing again, the weight is different, the fatigue is new, and someone tells her it is perimenopause. Sometimes that is the whole answer. Often it is both, layered, with the metabolic piece of PMOS driving symptoms that get written off as ordinary midlife change.
You can have PMOS and perimenopause at the same time. Sorting out which is doing what requires actual labs and an actual history, not a guess based on your age.
Common Questions
Is PMOS the same condition as PCOS?
Do I need to be re-diagnosed or re-tested?
Did the treatment recommendations change?
Will my chart, labs, and insurance still say PCOS?
Can you have PMOS without cysts on an ultrasound?
Is insulin resistance always part of it?
Can PMOS be diagnosed in your 40s?
Related Reading
Bring us the whole picture.
We evaluate hormonal and metabolic health together, because your symptoms deserve a real workup instead of a reassuring glance at an ultrasound.
Women's Hormone OptimizationTeede HJ, Bahri Khomami M, Morman R, et al; Global Name Change Consortium. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026;407(10545):2329-2339. doi:10.1016/S0140-6736(26)00717-8
With care,
Jessica Boggs, MSN, APRN, FNP-C, ENP-C · Navara Health